{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:33:13Z","timestamp":1792895593480,"version":"4.5.0"},"reference-count":82,"publisher":"Japanese Circulation Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2024,1,25]]},"DOI":"10.1253\/circj.cj-23-0838","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T22:11:17Z","timestamp":1702332677000},"page":"182-188","source":"Crossref","is-referenced-by-count":15,"title":["Shared and Reciprocal Mechanisms Between Heart Failure and Cancer\u3000\u2015 An Emerging Concept of Heart-Cancer Axis \u2015"],"prefix":"10.1253","volume":"88","author":[{"given":"Hiroshi","family":"Kadowaki","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Akazawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akito","family":"Shindo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[{"name":"Department of Frontier Cardiovascular Science, Graduate School of Medicine, The University of Tokyo"},{"name":"International University of Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Islami F, Ward EM, Sung H, Cronin KA, Tangka FKL, Sherman RL, et al. Annual report to the nation on the status of cancer, part 1: National cancer statistics. <i>J Natl Cancer Inst<\/i> 2021; 113: 1648\u20131669.","DOI":"10.1093\/jnci\/djab131"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kadowaki H, Akazawa H, Ishida J, Komuro I. Cancer therapeutics-related cardiac dysfunction: Insights from bench and bedside of onco-cardiology. <i>Circ J<\/i> 2020; 84: 1446\u20131453.","DOI":"10.1253\/circj.CJ-20-0467"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Oka T, Akazawa H, Sase K, Hatake K, Komuro I. Cardio-oncology in Japan: The rapidly rising sun. <i>JACC CardioOncol<\/i> 2020; 2: 815\u2013818.","DOI":"10.1016\/j.jaccao.2020.10.014"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and heart disease: Associations and relations. <i>Eur J Heart Fail<\/i> 2019; 21: 1515\u20131525.","DOI":"10.1002\/ejhf.1539"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. de Boer RA, Hulot JS, Tocchetti CG, Aboumsallem JP, Ameri P, Anker SD, et al. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>Eur J Heart Fail<\/i> 2020; 22: 2272\u20132289.","DOI":"10.1002\/ejhf.2029"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. de Wit S, Glen C, de Boer RA, Lang NN. Mechanisms shared between cancer, heart failure, and targeted anti-cancer therapies. <i>Cardiovasc Res<\/i> 2023; 118: 3451\u20133466.","DOI":"10.1093\/cvr\/cvac132"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hasin T, Gerber Y, McNallan SM, Weston SA, Kushwaha SS, Nelson TJ, et al. Patients with heart failure have an increased risk of incident cancer. <i>J Am Coll Cardiol<\/i> 2013; 62: 881\u2013886.","DOI":"10.1016\/j.jacc.2013.04.088"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hasin T, Gerber Y, Weston SA, Jiang R, Killian JM, Manemann SM, et al. Heart failure after myocardial infarction is associated with increased risk of cancer. <i>J Am Coll Cardiol<\/i> 2016; 68: 265\u2013271.","DOI":"10.1016\/j.jacc.2016.04.053"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Banke A, Schou M, Videbaek L, Moller JE, Torp-Pedersen C, Gustafsson F, et al. Incidence of cancer in patients with chronic heart failure: A long-term follow-up study. <i>Eur J Heart Fail<\/i> 2016; 18: 260\u2013266.","DOI":"10.1002\/ejhf.472"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Sakamoto M, Hasegawa T, Asakura M, Kanzaki H, Takahama H, Amaki M, et al. Does the pathophysiology of heart failure prime the incidence of cancer? <i>Hypertens Res<\/i> 2017; 40: 831\u2013836.","DOI":"10.1038\/hr.2017.45"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Selvaraj S, Bhatt DL, Claggett B, Djousse L, Shah SJ, Chen J, et al. Lack of association between heart failure and incident cancer. <i>J Am Coll Cardiol<\/i> 2018; 71: 1501\u20131510.","DOI":"10.1016\/j.jacc.2018.01.069"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Schwartz B, Schou M, Gislason GH, Kober L, Torp-Pedersen C, Andersson C. Prevalence and incidence of various cancer subtypes in patients with heart failure vs matched controls. <i>Int J Cardiol<\/i> 2020; 316: 209\u2013213.","DOI":"10.1016\/j.ijcard.2020.05.035"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kwak S, Kwon S, Lee SY, Yang S, Lee HJ, Lee H, et al. Differential risk of incident cancer in patients with heart failure: A nationwide population-based cohort study. <i>J Cardiol<\/i> 2021; 77: 231\u2013238.","DOI":"10.1016\/j.jjcc.2020.07.026"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Roderburg C, Loosen SH, Jahn JK, Gansbacher J, Luedde T, Kostev K, et al. Heart failure is associated with an increased incidence of cancer diagnoses. <i>ESC Heart Fail<\/i> 2021; 8: 3628\u20133633.","DOI":"10.1002\/ehf2.13421"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Bertero E, Robusto F, Rulli E, D\u2019Ettorre A, Bisceglia L, Staszewsky L, et al. Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort. <i>JACC CardioOncol<\/i> 2022; 4: 98\u2013109.","DOI":"10.1016\/j.jaccao.2021.11.007"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Paterson DI, Wiebe N, Cheung WY, Mackey JR, Pituskin E, Reiman A, et al. Incident cardiovascular disease among adults with cancer: A population-based cohort study. <i>JACC CardioOncol<\/i> 2022; 4: 85\u201394.","DOI":"10.1016\/j.jaccao.2022.01.100"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Camilli M, Chiabrando JG, Lombardi M, Del Buono MG, Montone RA, Lombardo A, et al. Cancer incidence and mortality in patients diagnosed with heart failure: Results from an updated systematic review and meta-analysis. <i>Cardiooncology<\/i> 2023; 9: 8.","DOI":"10.1186\/s40959-023-00158-1"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. <i>J Am Coll Cardiol<\/i> 2012; 59: 998\u20131005.","DOI":"10.1016\/j.jacc.2011.11.040"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lund LH, Donal E, Oger E, Hage C, Persson H, Haugen-Lofman I, et al. Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction. <i>Eur J Heart Fail<\/i> 2014; 16: 992\u20131001.","DOI":"10.1002\/ejhf.137"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kitai T, Miyakoshi C, Morimoto T, Yaku H, Murai R, Kaji S, et al. Mode of death among Japanese adults with heart failure with preserved, midrange, and reduced ejection fraction. <i>JAMA Netw Open<\/i> 2020; 3: e204296.","DOI":"10.1001\/jamanetworkopen.2020.4296"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hamaguchi S, Kinugawa S, Sobirin MA, Goto D, Tsuchihashi-Makaya M, Yamada S, et al. Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: Report from the registry of hospitalized heart failure patients. <i>Circ J<\/i> 2012; 76: 1662\u20131669.","DOI":"10.1253\/circj.CJ-11-1355"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Khan MS, Samman Tahhan A, Vaduganathan M, Greene SJ, Alrohaibani A, Anker SD, et al. Trends in prevalence of comorbidities in heart failure clinical trials. <i>Eur J Heart Fail<\/i> 2020; 22: 1032\u20131042.","DOI":"10.1002\/ejhf.1818"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, et al. Mode of death in patients with heart failure and a preserved ejection fraction: Results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. <i>Circulation<\/i> 2010; 121: 1393\u20131405.","DOI":"10.1161\/CIRCULATIONAHA.109.909614"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. <i>N Engl J Med<\/i> 2014; 370: 1383\u20131392.","DOI":"10.1056\/NEJMoa1313731"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Vaduganathan M, Patel RB, Michel A, Shah SJ, Senni M, Gheorghiade M, et al. Mode of death in heart failure with preserved ejection fraction. <i>J Am Coll Cardiol<\/i> 2017; 69: 556\u2013569.","DOI":"10.1016\/j.jacc.2016.10.078"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Vergaro G, Ghionzoli N, Innocenti L, Taddei C, Giannoni A, Valleggi A, et al. Noncardiac versus cardiac mortality in heart failure with preserved, midrange, and reduced ejection fraction. <i>J Am Heart Assoc<\/i> 2019; 8: e013441.","DOI":"10.1161\/JAHA.119.013441"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>N Engl J Med<\/i> 2014; 371: 993\u20131004.","DOI":"10.1056\/NEJMoa1409077"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tini G, Bertero E, Signori A, Sormani MP, Maack C, De Boer RA, et al. Cancer mortality in trials of heart failure with reduced ejection fraction: A systematic review and meta-analysis. <i>J Am Heart Assoc<\/i> 2020; 9: e016309.","DOI":"10.1161\/JAHA.119.016309"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, et al. Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study. <i>J Clin Oncol<\/i> 2016; 34: 1122\u20131130.","DOI":"10.1200\/JCO.2015.64.0409"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Strongman H, Gadd S, Matthews A, Mansfield KE, Stanway S, Lyon AR, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: A population-based cohort study using multiple linked UK electronic health records databases. <i>Lancet<\/i> 2019; 394: 1041\u20131054.","DOI":"10.1016\/S0140-6736(19)31674-5"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Dobbin SJH, Shen L, Petrie MC, Packer M, Solomon SD, McMurray JJV, et al. Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials. <i>Eur J Heart Fail<\/i> 2023; 25: 488\u2013496.","DOI":"10.1002\/ejhf.2818"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Labib D, Satriano A, Dykstra S, Hansen R, Mikami Y, Guzzardi DG, et al. Effect of active cancer on the cardiac phenotype: A cardiac magnetic resonance imaging-based study of myocardial tissue health and deformation in patients with chemotherapy-naive cancer. <i>J Am Heart Assoc<\/i> 2021; 10: e019811.","DOI":"10.1161\/JAHA.120.019811"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. <i>Circulation<\/i> 2016; 133: 1104\u20131114.","DOI":"10.1161\/CIRCULATIONAHA.115.020406"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. <i>Cardiovasc Res<\/i> 2019; 115: 844\u2013853.","DOI":"10.1093\/cvr\/cvz035"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: The American Heart Association\u2019s strategic Impact Goal through 2020 and beyond. <i>Circulation<\/i> 2010; 121: 586\u2013613.","DOI":"10.1161\/CIRCULATIONAHA.109.192703"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Rasmussen-Torvik LJ, Shay CM, Abramson JG, Friedrich CA, Nettleton JA, Prizment AE, et al. Ideal cardiovascular health is inversely associated with incident cancer: The Atherosclerosis Risk In Communities study. <i>Circulation<\/i> 2013; 127: 1270\u20131275.","DOI":"10.1161\/CIRCULATIONAHA.112.001183"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Ogunmoroti O, Allen NB, Cushman M, Michos ED, Rundek T, Rana JS, et al. Association between Life\u2019s Simple 7 and noncardiovascular disease: The Multi-Ethnic Study of Atherosclerosis. <i>J Am Heart Assoc<\/i> 2016; 5: e003954.","DOI":"10.1161\/JAHA.116.003954"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Foraker RE, Abdel-Rasoul M, Kuller LH, Jackson RD, Van Horn L, Seguin RA, et al. Cardiovascular health and incident cardiovascular disease and cancer: The Women\u2019s Health Initiative. <i>Am J Prev Med<\/i> 2016; 50: 236\u2013240.","DOI":"10.1016\/j.amepre.2015.07.039"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Lau ES, Paniagua SM, Liu E, Jovani M, Li SX, Takvorian K, et al. Cardiovascular risk factors are associated with future cancer. <i>JACC CardioOncol<\/i> 2021; 3: 48\u201358.","DOI":"10.1016\/j.jaccao.2020.12.003"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Van Sloten T, Valentin E, Climie RE, Deraz O, Weiderpass E, Jouven X, et al. Association of midlife cardiovascular health and subsequent change in cardiovascular health with incident cancer. <i>JACC CardioOncol<\/i> 2023; 5: 39\u201352.","DOI":"10.1016\/j.jaccao.2022.11.015"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Mann DL, Felker GM. Mechanisms and models in heart failure: A translational approach. <i>Circ Res<\/i> 2021; 128: 1435\u20131450.","DOI":"10.1161\/CIRCRESAHA.121.318158"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Cole SW, Nagaraja AS, Lutgendorf SK, Green PA, Sood AK. Sympathetic nervous system regulation of the tumour microenvironment. <i>Nat Rev Cancer<\/i> 2015; 15: 563\u2013572.","DOI":"10.1038\/nrc3978"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Kamo T, Akazawa H, Komuro I. Pleiotropic effects of angiotensin II receptor signaling in cardiovascular homeostasis and aging. <i>Int Heart J<\/i> 2015; 56: 249\u2013254.","DOI":"10.1536\/ihj.14-429"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: Old dog, new tricks. <i>Nat Rev Cancer<\/i> 2010; 10: 745\u2013759.","DOI":"10.1038\/nrc2945"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. <i>Sci Transl Med<\/i> 2017; 9: eaan5616.","DOI":"10.1126\/scitranslmed.aan5616"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. <i>Proc Natl Acad Sci U S A<\/i> 2009; 106: 10284\u201310289.","DOI":"10.1073\/pnas.0900351106"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Cortez-Retamozo V, Etzrodt M, Newton A, Ryan R, Pucci F, Sio SW, et al. Angiotensin II drives the production of tumor-promoting macrophages. <i>Immunity<\/i> 2013; 38: 296\u2013308.","DOI":"10.1016\/j.immuni.2012.10.015"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Libby P, Kobold S. Inflammation: A common contributor to cancer, aging, and cardiovascular diseases: Expanding the concept of cardio-oncology. <i>Cardiovasc Res<\/i> 2019; 115: 824\u2013829.","DOI":"10.1093\/cvr\/cvz058"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. <i>Nat Rev Cardiol<\/i> 2020; 17: 269\u2013285.","DOI":"10.1038\/s41569-019-0315-x"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Everett BM, Cornel JH, Lainscak M, Anker SD, Abbate A, Thuren T, et al. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. <i>Circulation<\/i> 2019; 139: 1289\u20131299.","DOI":"10.1161\/CIRCULATIONAHA.118.038010"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Greten FR, Grivennikov SI. Inflammation and cancer: Triggers, mechanisms, and consequences. <i>Immunity<\/i> 2019; 51: 27\u201341.","DOI":"10.1016\/j.immuni.2019.06.025"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial. <i>Lancet<\/i> 2017; 390: 1833\u20131842.","DOI":"10.1016\/S0140-6736(17)32247-X"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. <i>Nat Med<\/i> 2014; 20: 1472\u20131478.","DOI":"10.1038\/nm.3733"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Genovese G, Kahler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. <i>N Engl J Med<\/i> 2014; 371: 2477\u20132487.","DOI":"10.1056\/NEJMoa1409405"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. <i>N Engl J Med<\/i> 2014; 371: 2488\u20132498.","DOI":"10.1056\/NEJMoa1408617"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Khetarpal SA, Qamar A, Bick AG, Fuster JJ, Kathiresan S, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential reshapes age-related CVD: JACC review topic of the week. <i>J Am Coll Cardiol<\/i> 2019; 74: 578\u2013586.","DOI":"10.1016\/j.jacc.2019.05.045"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Sano S, Wang Y, Walsh K. Clonal hematopoiesis and its impact on cardiovascular disease. <i>Circ J<\/i> 2018; 83: 2\u201311.","DOI":"10.1253\/circj.CJ-18-0871"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Tall AR, Fuster JJ. Clonal hematopoiesis in cardiovascular disease and therapeutic implications. <i>Nat Cardiovasc Res<\/i> 2022; 1: 116\u2013124.","DOI":"10.1038\/s44161-021-00015-3"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. <i>N Engl J Med<\/i> 2017; 377: 111\u2013121.","DOI":"10.1056\/NEJMoa1701719"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Zuriaga MA, Fuster JJ. Emerging role of acquired mutations and clonal hematopoiesis in atherosclerosis: Beyond conventional cardiovascular risk factors. <i>Circ J<\/i> 2023; 87: 394\u2013400.","DOI":"10.1253\/circj.CJ-21-0505"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. Yura Y, Sano S, Walsh K. Clonal hematopoiesis: A new step linking inflammation to heart failure. <i>JACC Basic Transl Sci<\/i> 2020; 5: 196\u2013207.","DOI":"10.1016\/j.jacbts.2019.08.006"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Sikking MA, Stroeks S, Waring OJ, Henkens M, Riksen NP, Hoischen A, et al. Clonal hematopoiesis of indeterminate potential from a heart failure specialist\u2019s point of view. <i>J Am Heart Assoc<\/i> 2023; 12: e030603.","DOI":"10.1161\/JAHA.123.030603"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Sano S, Oshima K, Wang Y, MacLauchlan S, Katanasaka Y, Sano M, et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta\/NLRP3 inflammasome. <i>J Am Coll Cardiol<\/i> 2018; 71: 875\u2013886.","DOI":"10.1016\/j.jacc.2017.12.037"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Sano S, Oshima K, Wang Y, Katanasaka Y, Sano M, Walsh K. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. <i>Circ Res<\/i> 2018; 123: 335\u2013341.","DOI":"10.1161\/CIRCRESAHA.118.313225"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Mas-Peiro S, Hoffmann J, Fichtlscherer S, Dorsheimer L, Rieger MA, Dimmeler S, et al. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. <i>Eur Heart J<\/i> 2020; 41: 933\u2013939.","DOI":"10.1093\/eurheartj\/ehz591"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Sano S, Wang Y, Yura Y, Sano M, Oshima K, Yang Y, et al. JAK2 (V617F)-mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure. <i>JACC Basic Transl Sci<\/i> 2019; 4: 684\u2013697.","DOI":"10.1016\/j.jacbts.2019.05.013"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, et al. Heart failure stimulates tumor growth by circulating factors. <i>Circulation<\/i> 2018; 138: 678\u2013691.","DOI":"10.1161\/CIRCULATIONAHA.117.030816"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Avraham S, Abu-Sharki S, Shofti R, Haas T, Korin B, Kalfon R, et al. Early cardiac remodeling promotes tumor growth and metastasis. <i>Circulation<\/i> 2020; 142: 670\u2013683.","DOI":"10.1161\/CIRCULATIONAHA.120.046471"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Awwad L, Aronheim A. Cardiac dysfunction promotes cancer progression via multiple secreted factors. <i>Cancer Res<\/i> 2022; 82: 1753\u20131761.","DOI":"10.1158\/0008-5472.CAN-21-2463"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Koelwyn GJ, Newman AAC, Afonso MS, van Solingen C, Corr EM, Brown EJ, et al. Myocardial infarction accelerates breast cancer via innate immune reprogramming. <i>Nat Med<\/i> 2020; 26: 1452\u20131458.","DOI":"10.1038\/s41591-020-0964-7"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Argiles JM, Lopez-Soriano FJ, Stemmler B, Busquets S. Cancer-associated cachexia: Understanding the tumour macroenvironment and microenvironment to improve management. <i>Nat Rev Clin Oncol<\/i> 2023; 20: 250\u2013264.","DOI":"10.1038\/s41571-023-00734-5"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Barkhudaryan A, Scherbakov N, Springer J, Doehner W. Cardiac muscle wasting in individuals with cancer cachexia. <i>ESC Heart Fail<\/i> 2017; 4: 458\u2013467.","DOI":"10.1002\/ehf2.12184"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM, et al. Causes of death among cancer patients. <i>Ann Oncol<\/i> 2017; 28: 400\u2013407.","DOI":"10.1093\/annonc\/mdw604"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. Anker MS, Sanz AP, Zamorano JL, Mehra MR, Butler J, Riess H, et al. Advanced cancer is also a heart failure syndrome: A hypothesis. <i>Eur J Heart Fail<\/i> 2021; 23: 140\u2013144.","DOI":"10.1002\/ejhf.2071"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A, et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. <i>Eur Heart J<\/i> 2014; 35: 932\u2013941.","DOI":"10.1093\/eurheartj\/eht302"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. Stevens SC, Velten M, Youtz DJ, Clark Y, Jing R, Reiser PJ, et al. Losartan treatment attenuates tumor-induced myocardial dysfunction. <i>J Mol Cell Cardiol<\/i> 2015; 85: 37\u201347.","DOI":"10.1016\/j.yjmcc.2015.05.007"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. Karlstaedt A, Barrett M, Hu R, Gammons ST, Ky B. Cardio-oncology: Understanding the intersections between cardiac metabolism and cancer biology. <i>JACC Basic Transl Sci<\/i> 2021; 6: 705\u2013718.","DOI":"10.1016\/j.jacbts.2021.05.008"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy. <i>Nat Rev Clin Oncol<\/i> 2021; 18: 645\u2013661.","DOI":"10.1038\/s41571-021-00521-0"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. Akbay EA, Moslehi J, Christensen CL, Saha S, Tchaicha JH, Ramkissoon SH, et al. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. <i>Genes Dev<\/i> 2014; 28: 479\u2013490.","DOI":"10.1101\/gad.231233.113"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. Karlstaedt A, Zhang X, Vitrac H, Harmancey R, Vasquez H, Wang JH, et al. Oncometabolite D-2-hydroxyglutarate impairs alpha-ketoglutarate dehydrogenase and contractile function in rodent heart. <i>Proc Natl Acad Sci USA<\/i> 2016; 113: 10436\u201310441.","DOI":"10.1073\/pnas.1601650113"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer: Implications for future improvements in cancer care. <i>Nat Rev Clin Oncol<\/i> 2018; 15: 617\u2013638.","DOI":"10.1038\/s41571-018-0036-9"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. Gargiulo P, Marzano F, Salvatore M, Basile C, Buonocore D, Parlati ALM, et al. MicroRNAs: Diagnostic, prognostic and therapeutic role in heart failure: A review. <i>ESC Heart Fail<\/i> 2023; 10: 753\u2013761.","DOI":"10.1002\/ehf2.14153"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/88\/2\/88_CJ-23-0838\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:50:26Z","timestamp":1715575826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/88\/2\/88_CJ-23-0838\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-23-0838","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"article-number":"CJ-23-0838"}}